



Protecting the Autonomy of Industry Regulators

What is the issue?

\n\n

\n

- Chairman of the “National Pharmaceutical Pricing Authority” (NPPA), Mr. Bhupendra Singh was recently ousted ahead of time without a replacement.
- There seems to lack of transparency and credibility in the appointments and removals at multiple regulatory bodies in the country.

\n

\n\n

What creates suspicion?

\n\n

\n

- **NPPA** - NPPA is the pricing regulator for medicines and medical devices in the country and works under the Union Ministry of Chemical and Fertilizers.

\n

\n\n

\n

- Mr. Bhupendra was moved out ahead of time, after a little over two years at the helm of NPPA even before identifying a replacement.
- Notably, his predecessor Mr. Injeti Srinivas was also transferred out in less than a year of assuming office.
- These episodes are particularly uncomfortable because there seems to be a possible industry pressure in the ouster of these chairpersons.
- Notably, both these people had taken critical action on drugs and medical devices manufacturers and established price controls for medical implants.

\n

- These were actually laudable efforts to bust inflated distribution margins (up to 1000% plus in some cases) on cardiac stents and other consumables.

\n

\n\n

\n

- **DCGI** - DCGI's office is entrusted with giving approvals to drugs and other products marketed in the country and works under the Union Health Ministry.

\n

- Dr. GN Singh, who has had a respectable tenure as the “Drug Controller General of India” (DCGI) was recently replaced arbitrarily.

\n

- It is also tasked with inspecting drug manufacturing facilities across the country, besides watching over all clinical trials (both animals and humans).

\n

- GN Singh’s tenure saw significant action in cleaning up the clinical trials segment and the sale of fixed-dose combination medicines in the country.

\n

- **Others** - There were a bunch of inexplicable transfers in the health ministry, including that of “Director General of Health Services” Dr Jagdish Prasad.

\n

\n\n

What is the way ahead?

\n\n

\n

- **The Malice** - While one can’t prove that industry pressure caused the ouster of these people from office, there is ample scope for speculation in that regard.

\n

- Considering the harsh manner in which the above officers were shunted out, it gives little incentive for a new person in office to operate independently.

\n

- The high-headed approach of the government is likely to erode the institutional credibility of regulators, which is of serious concern.

\n

- **Way Forward** - Instead of muzzling the regulators, the government needs to groom probable candidates with the right scientific and administrative skills.

\n

- Regulators need functional autonomy, and a fixed term (say five years) to implement policies and better structure regulations

\n

- And if anyone is removed before their term ends, it needs to be for inefficiency or corruption and that reason needs to be made public.

\n

- Stakeholder involvement in policy formulations needs to be enhanced by regularly engaging - the pharma industry, health service providers and the civil society at large.

\n

\n\n

\n\n

Source: Indian Express

\n\n

\n\n

\n



IAS PARLIAMENT

Information is Empowering

A Shankar IAS Academy Initiative